C.M. Bidwell & Associates’s Neurocrine Biosciences NBIX Stock Holding History

C.M. Bidwell & Associates’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$231K	Buy	+1,369	New	+$203K	0.09%	136
2024 Q1	–	Sell	-894	Closed	-$118K	–	528
2023 Q4	$118K	Buy	894 +5	+0.6%	+$576	0.09%	147
2023 Q3	$100K	Buy	+889	New	+$93.6K	0.08%	230
2023 Q1	–	Sell	-419	Closed	-$50K	–	544
2022 Q4	$50K	Hold	419	–	–	0.04%	288
2022 Q3	$45K	Buy	+419	New	+$42.5K	0.04%	279
2018 Q4	–	Sell	-275	Closed	-$34K	–	441
2018 Q3	$34K	Buy	+275	New	+$31.2K	0.03%	257

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

C.M. Bidwell & Associates's NBIX Position: Q2 2026 in Review

C.M. Bidwell & Associates opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,369 shares worth $231K. The stake represents 0.09% of the portfolio and ranks #136 among its holdings. This is a return to the name: C.M. Bidwell & Associates previously reported a position in NBIX as recently as Q4 2023.

C.M. Bidwell & Associates first reported a position in NBIX in Q3 2018 and has held it in 6 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

C.M. Bidwell & Associates held 1,369 shares of Neurocrine Biosciences worth $231K as of Q2 2026.
Neurocrine Biosciences was a new C.M. Bidwell & Associates position in Q2 2026.
Neurocrine Biosciences made up 0.09% of C.M. Bidwell & Associates's portfolio in Q2 2026, its #136 holding.
C.M. Bidwell & Associates first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 6 quarters since.
777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2026, filed 11 Aug 2026.